



Setting new standards in minimally-invasive tumor therapy for women's health and interventional oncology

ABOUT ICECURE MEDICAL

IceCure has developed a next-generation cryoablation technology platform, based on advanced liquid nitrogen treatment, that uses freezing temperatures to destroy tumors safely, quickly and painlessly without the need for surgery.

Commercially available in the U.S.A., Europe, Hong-Kong, Thailand, Singapore and South- Central America, its flagship system, ProSense® enables rapid, minimally-invasive and effective treatment of tumors in office or ambulatory hospital settings.

LIQUID NITROGEN

Next Generation "Liquid Nitrogen" Cryoablation Technology Platform

IceCure's proprietary, third-generation liquid-nitrogen-based technology generates lower tissue temperatures and a faster cooling rate than other methods, to enable a larger ice-ball tumor killing area for maximum efficacy.

WIDE MARKET APPLICATIONS



BREAST



KIDNEY



LUNG



LIVER



BONE



PROSTATE*

*Selected applications are already FDA cleared.



PATENTED, CLINICALLY
VALIDATED CRYOABLATION
TECHNOLOGY



TRADED PUBLIC COMPANY;
\$40 MILLION RAISED
(TASE: ICCM)



FDA & CE APPROVED



OUTSTANDING INITIAL
CLINICAL RESULTS



SUPPORTED BY KEY
OPINION LEADERS
WORLDWIDE

THE PROSENSE® SYSTEM

The ProSense® system offers an ultrasound / CT probe-guided treatment that generates sub-zero temperatures to turn the tumor into an ice ball for accurate destruction of diseased tissue, while leaving surrounding tissue unharmed.

- Easy-to-use, customizable system
- Full physician control over procedure (automatic and manual)
- Real-time imaging & monitoring
- Various sized probes for targeted iceball formation & tissue destruction
- Rapid in-office/CT procedure
- High patient satisfaction and fast recovery

CLINICALLY PROVEN

Clinical studies conducted worldwide demonstrate that cryoablation is safe and effective in treating a wide variety of tumors, including breast, kidney, lung, liver, bone and prostate.



"Cryoablation is a procedure that we know is safe, efficacious, cost effective and cosmetically superior to surgical removal. IceCure has improved upon the technology and developed a system optimized for breast fibroadenoma. My patients have been very happy with the short, painless procedure, and the ability to return to normal activity immediately."

Andrew Kenler, MD, FACS

ICE3 - LANDMARK US CLINICAL TRIAL

ICE3 is the largest controlled multilocation clinical trial ever performed for nitrogen-based cryoablation of small, low-risk, early-stage malignant breast tumors without subsequently removing them. The trial began in 2014 and involves 19 hospitals and medical centers across the US, including Columbia University Medical Center and Mount Sinai Beth Israel. An initial overview of the ICE3 trial was presented at the Annual Meeting of The American Society of Breast Surgeons.

The ASBrS has published modified guidelines in favor of cryoablation.

PROMISING INITIAL RESULTS IN RENAL CANCER



Presented at the 34th Annual European Association of Urology Congress, the ProSense® system was safe, effective and without serious adverse events in the treatment of small kidney tumors. In 74 patients with 78 small kidney masses (up to 4cm) treated, ProSense® showed treatment success by lack of enhancement on CT or MRI in 93% (42 of 45) cases at 1 year follow-up.

Contact
IceCure
Medical

Headquarters

IceCure Medical, Ltd
7 Haeshel St., POB 3163
Caesarea 3079504 Israel
T +972-4-6230333
F +972-4-6230222

USA

IceCure Medical Inc.
T +1-888-902-5716

 IceCure
Innovating Cryotherapy Solutions

www.icecure-medical.com